LIPOCINE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.798 USD | +5.44% |
|
-8.96% | +71.96% |
| Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
| Apr. 11 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13.8 | 89.33 | 87.5 | 35.21 | 14.83 | 25.5 |
| Enterprise Value (EV) 1 | 13.8 | 89.33 | 87.5 | 35.21 | 14.83 | 25.5 |
| P/E ratio | -0.77 x | -3.58 x | -99.1 x | -3.32 x | -0.9 x | -3.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 83.6 x | - | 5.42 x | 70.4 x | -5.2 x | 12.6 x |
| EV / Revenue | 83.6 x | - | 5.42 x | 70.4 x | -5.2 x | 12.6 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,109 | 3,864 | 5,194 | 5,207 | 5,316 | 5,316 |
| Reference price 2 | 6.543 | 23.12 | 16.85 | 6.763 | 2.790 | 4.798 |
| Announcement Date | 3/13/20 | 3/11/21 | 3/9/22 | 3/10/23 | 3/7/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.165 | - | 16.14 | 0.5 | -2.851 | 2.026 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -12.9 | -18 | 3.146 | -12.12 | -17.93 | -13.41 |
| Operating Margin | -7,818.83% | - | 19.49% | -2,423.88% | 628.98% | -661.7% |
| Earnings before Tax (EBT) 1 | -13.01 | -20.96 | -0.6342 | -10.76 | -16.35 | -13.21 |
| Net income 1 | -13.01 | -20.96 | -0.6344 | -10.76 | -16.35 | -12.55 |
| Net margin | -7,883.71% | - | -3.93% | -2,151.73% | 573.6% | -619.25% |
| EPS 2 | -8.500 | -6.460 | -0.1700 | -2.040 | -3.100 | -1.490 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/13/20 | 3/11/21 | 3/9/22 | 3/10/23 | 3/7/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.055 | 16.09 | - | 0.5 | - | - | 0.055 | - | -3.122 | 0.2162 | - | 0.405 | 0.547 | 1.074 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.534 | 12.78 | -3.132 | -3.528 | -2.899 | -2.561 | -4.339 | -3.956 | -7.043 | -2.593 | -3.725 | -3.406 | -3.354 | -2.92 |
| Operating Margin | -6,426.02% | 79.47% | - | -705.51% | - | - | -7,889.85% | - | 225.6% | -1,199.57% | - | -840.99% | -613.16% | -271.88% |
| Earnings before Tax (EBT) 1 | -3.081 | 12.62 | -3.488 | -2.632 | -2.409 | -2.229 | -3.87 | -3.549 | -6.651 | -2.282 | -3.675 | -3.356 | -3.304 | -2.87 |
| Net income 1 | -3.081 | 12.62 | -3.488 | -2.632 | -2.409 | -2.23 | -3.87 | -3.549 | -6.651 | -2.282 | -3.675 | -3.356 | -3.304 | -2.87 |
| Net margin | -5,603.38% | 78.48% | - | -526.36% | - | - | -7,038.06% | - | 213.04% | -1,055.71% | - | -828.64% | -604.02% | -267.23% |
| EPS 2 | -0.5100 | 2.380 | -0.6800 | -0.5100 | -0.5100 | -0.3400 | -0.6800 | -0.6800 | -1.260 | -0.4200 | -0.6800 | -0.6200 | -0.2900 | -0.2500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/9/22 | 5/9/22 | 8/8/22 | 11/9/22 | 3/10/23 | 5/11/23 | 8/10/23 | 11/8/23 | 3/7/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | 0.01 | 0.13 | - | - |
| Capex / Sales | - | - | 0.05% | 26.77% | - | - |
| Announcement Date | 3/13/20 | 3/11/21 | 3/9/22 | 3/10/23 | 3/7/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.798
USD
Average target price
33
USD
Spread / Average Target
+587.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +71.96% | 25.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LPCN Stock
- Financials Lipocine Inc.
